Omniab Inc Revenue Growth Rates (OABI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Omniab Inc   (NASDAQ: OABI)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

OABI's Revenue Growth by Quarter and Year

Omniab Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/OABI/growth
https://api.csimarket.com/api/v1/companies/OABI/fundamentals
https://api.csimarket.com/api/v1/companies/OABI/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
OABI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.99
2nd Quarter June 13.42
1st Quarter March 14.43
FY 31.84

OABIs Annual Revenue
Omniab Inc 's Revenue in the fiscal year 2025 $ 18.67 millions
Omniab Inc 's Revenue in the fiscal year 2024 $ 26.39 millions
Omniab Inc 's Revenue in the fiscal year 2023 $ 34.16 millions
Omniab Inc 's Revenue in the fiscal year 2022 $ 59.08 millions
Omniab Inc 's Revenue in the fiscal year 2021 $ 34.75 millions




OABI Revenue third quarter 2026 Y/Y Growth Comment
Omniab Inc achieved in the third quarter 2026, above Company average Revenue rise of 78.26% year on year, to $ 3.99 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 2 other companies have achieved higher Revenue growth. While Omniab Inc ' s Revenue jump of 78.26% ranks overall at the positon no. 340 in the third quarter 2026.


OABI Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 78.26 %
2nd Quarter June 244.1 %
1st Quarter March 247.71 %
FY   -

Financial Statements
Omniab Inc 's third quarter 2026 Revenue $ 3.99 millions OABI's Income Statement
Omniab Inc 's third quarter 2025 Revenue $ 2.24 millions Quarterly OABI's Income Statement


OABI Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -70.25 %
2nd Quarter June -7 %
1st Quarter March 72.2 %
FY (Year on Year)   -


Back to OABI Growth rate Comparisons >> Back to OABI Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #90
Overall #340

Revenue Y/Y Growth Statistics
High Average Low
247.3 % 30.6 % -86.36 %
(Jun 30 2026)   (Sep 30 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #90
Overall #340
Revenue Y/Y Growth Statistics
High Average Low
247.3 % 30.6 % -86.36 %
(Jun 30 2026)   (Sep 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Omniab Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
411.51 % 38.83 % -61.55 %
(Dec 31 2022)  


OABI's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Omniab Inc disclosed fall in Revenue from the second quarter by -70.25% to $ 3.99 millions, from $ 13.42 millions achived in the previous reporting period.

But that's not important problem, as Omniab Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Omniab Inc 's Revenue growth quarter on quarter, overall rank is 2646.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #328
Overall #2646
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #328
Overall #2646
Revenue Q/Q Growth Statistics
High Average Low
411.51 % 38.83 % -61.55 %
(Dec 31 2022)  


OABI's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Omniab Inc disclosed fall in Revenue from the second quarter by -70.25% to $ 3.99 millions, from $ 13.42 millions achived in the previous reporting period.

But that's not important problem, as Omniab Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Omniab Inc 's Revenue growth quarter on quarter, overall rank is 2646.


Omniab Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 40.21
Y / Y Revenue Growth (TTM) 90.63 %
Year on Year Revenue Growth Overall Ranking # 1957
Seqeuential Revenue Change (TTM) 4.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 3306


Cumulative Revenue growth Comment
Omniab Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 90.63% year on year, to $ 40 millions if the fiscal year would have ended in Sep 30 2026.
Omniab Inc 's trailing twelve months Revenue growth was higher than company's average -16.95% and higher than 67.01% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 4.56 % from $38.46 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -16.95%.

In the Healthcare sector 301 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1957, from total ranking in previous quarter at 2333.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 302
Overall # 1957

Revenue TTM Y/Y Growth Statistics
High Average Low
67.01 %
 -16.95 %
-68.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 440
S&P 500 # 3306
Cumulative Revenue growth Comment
Omniab Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 90.63% year on year, to $ 40 millions if the fiscal year would have ended in Sep 30 2026.
Omniab Inc 's trailing twelve months Revenue growth was higher than company's average -16.95% and higher than 67.01% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 4.56 % from $38.46 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -16.95%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 4.56 % increase from $38.46 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 301 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1957, from total ranking in previous quarter at 2333.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 302
Overall # 1957

Revenue TTM Y/Y Growth Statistics
High Average Low
67.01 %
-16.95 %
-68.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 440
S&P 500 # 3306




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OABI's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions


About Omniab Inc Revenue Growth Rates (OABI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Omniab Inc (CIK 1846253).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001846253-26-000051
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Omniab Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.